Literature DB >> 16688824

Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.

Chii-Shyan Lay1, C-M-Y May, Fa-Yauh Lee, Yang-Te Tsai, Shou-Dong Lee, Shu Chien, Shlomoh Sinchon.   

Abstract

AIM: To investigate the effects of verapamil on nitric oxide (NO) synthesis in a portal vein-ligated rat model.
METHODS: Systemic and splanchnic hemodynamics were measured by radiolabeled microspheres in portal hypertensive rats after acute administration of verapamil (2 mg/kg) on chronic treatment with N(w)-nitro-L-arginine (NNA)(80 mg/kg) and/or indomethacin (2 mg/kg).
RESULTS: Verapamil (2 mg/kg) caused a marked fall in both arterial pressure and cardiac output accompanied by an insignificant change in the portal pressure and no change in portal venous inflow. This result suggested that verapamil did not cause a reduction in portal vascular resistance of portal hypertensive rats, which was similar between N(w)- nitro-L-arginine-treated and indomethacin-treated groups.
CONCLUSION: In portal hypertensive rats pretreated with NNA and/or indomethacin, acute verapamil administration can not reduce the portal pressure, suggesting that NO and prostaglandin play an important role in the pathogenesis of splanchnic arterial vasodilation in portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688824      PMCID: PMC4088069          DOI: 10.3748/wjg.v12.i15.2351

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.

Authors:  J G Freeman; J R Barton; C O Record
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

2.  Medical treatments for bleeding esophageal varices.

Authors:  C S Lay; Y T Tsai; K J Lo; S D Lee; T S Chen; F Y Lee
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

3.  Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis.

Authors:  A Koshy; A Hadengue; S S Lee; M I Jiron; D Lebrec
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

4.  The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice.

Authors:  Nicholas G Theodorakis; Yi-Ning Wang; Nicholas J Skill; Matthew A Metz; Paul A Cahill; Eileen M Redmond; James V Sitzmann
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use.

Authors:  B N Singh; G Ellrodt; C T Peter
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

6.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

7.  Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis.

Authors:  J Reichen; A Hirlinger; H R Ha; S Sägesser
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

Review 8.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

9.  Effects of calcium entry blockers on calcium-dependent contractions of rat portal vein.

Authors:  C Dacquet; C Mironneau; J Mironneau
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

10.  The hemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis.

Authors:  C W Kong; C S Lay; Y T Tsai; C L Yeh; K H Lai; S D Lee; K J Lo; B N Chiang
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

View more
  1 in total

1.  Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Authors:  T Ohyama; K Sato; K Kishimoto; Y Yamazaki; N Horiguchi; T Ichikawa; S Kakizaki; H Takagi; T Izumi; M Mori
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.